GLP-1 agonists: a real tool, and a clinician's call

The GLP-1 receptor agonists are the rare frontier-adjacent story where the evidence arrived before the hype curve peaked, not after. In the STEP 1 trial, semaglutide plus lifestyle produced about 15% mean body-weight loss over 68 weeks — a magnitude that previously belonged to surgery. More importantly, SELECT showed that in people with obesity and existing cardiovascular disease, it cut major cardiovascular events by 20%. That second result is the one that matters: this isn’t only about the scale, it’s about heart attacks and strokes that didn’t happen.

So the honest verdict is not skepticism. For the right person, this class does things lifestyle change alone rarely achieves, and the trial evidence is grade-A. It sits in the Rx tier not because it’s weak, but because it is a medication with medication-shaped trade-offs.

The adult context

The side effects are real — nausea, vomiting, and other GI effects are common, especially while titrating; some are enough to stop treatment. There are open questions about muscle loss during rapid weight loss (which is one reason resistance training and protein belong in the plan), about what happens when you stop (weight tends to return), and about the practicalities of cost and long-term use. None of these are reasons to fear the drug; they’re reasons it belongs in a monitored clinical relationship rather than a self-serve stack.

And the placement is deliberate. A GLP-1 is powerful, but it is not a foundation, and it works best layered on top of the foundations — training to protect muscle, the cardiometabolic numbers it improves. If you’re already lean, fit, and metabolically healthy, this isn’t your tier. If you’re carrying real cardiometabolic risk, it’s a conversation worth having with your clinician — clearly, without either the fear-mongering or the miracle-drug gloss.